Related Experiment Video
Updated: May 28, 2025
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary Hypertension in the Field of Hematological and Oncological Diseases
Mona Lichtblau1,2, Frédéric Lador3, Benoit Lechartier4
1Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Introduction:
Hematological and oncological diseases collectively affect a substantial number of patients. Pulmonary hypertension (PH) is recognized as a potential rare complication associated with these conditions, manifesting in various forms of PH and presenting with a range of symptoms. This review aimed to summarize recent research findings and enhance the understanding of the complex interactions between PH and hemato-oncological diseases.
Methods:
This narrative review synthesizes recent research findings to explore the interplay between PH and hematological or oncological diseases. A comprehensive search of relevant literature was conducted using PubMed.
Results:
The complexity of PH in this context arises from its multifactorial etiology, which can include direct effects of malignancies, treatment-related effects, and the impact of disease progression. The variability in how PH presents and progresses in patients with hematological diseases and neoplasms complicates its diagnosis and management. Accurate identification of PH alongside the underlying condition is crucial for enabling optimal treatment and improving overall survival. A multidisciplinary approach is essential to address these challenges effectively.
Conclusion:
PH in hematologic and oncologic diseases can result from multiple causes. Following a systematic workup, a multidisciplinary approach to management is crucial to ensure optimal treatment and improve survival.
More Related Videos
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...